Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.64
-1.21 (-6.78%)
Sep 21, 2026, 2:02 PM EDT - Market open
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
13.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Corcept Therapeutics | 830.81M |
SMMT News
- 6 days ago - Summit Therapeutics reports updated OS results from Phase 3 Harmoni trial - TheFly
- 6 days ago - Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients - Business Wire
- 8 days ago - Summit partner announces updated data from Phase III HARMONi-2 trial - TheFly
- 8 days ago - Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China - Business Wire
- 12 days ago - Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data - TheFly
- 12 days ago - Summit Therapeutics upgraded to Buy from Hold at Jefferies - TheFly
- 18 days ago - Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results - TipRanks
- 18 days ago - Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Business Wire